April 18, 2026 — As the U.S. Congress begins deliberations on the 2026 Farm Bill, early drafts released this week reveal significant proposed changes to hemp policy that could reshape the industry. Lawmakers are focusing on clarifying federal oversight, expanding research funding, and addressing lingering regulatory gaps for hemp-derived products, particularly cannabinoids like CBD.

Key Provisions in the Draft

The draft bill, circulated among agricultural committees, includes several provisions aimed at bolstering the hemp sector. First, it proposes to permanently codify hemp as a distinct agricultural commodity separate from marijuana, reinforcing the 2018 Farm Bill’s legalization of hemp with THC levels below 0.3%. This move aims to eliminate any remaining legal ambiguity at the federal level, providing certainty for farmers and businesses.

Additionally, the draft allocates increased funding for hemp research through the U.S. Department of Agriculture (USDA). This includes grants for studying hemp’s potential in sustainable agriculture, such as its use in crop rotation to improve soil health, and its applications in industrial products. The bill also calls for expanded pilot programs to explore new hemp cultivars with optimized cannabinoid profiles.

Addressing CBD Regulatory Uncertainty

Perhaps the most significant aspect for the CBD industry is the draft’s push for clearer federal guidelines on hemp-derived cannabinoids. While the Food and Drug Administration (FDA) has yet to establish a comprehensive framework for CBD in food, beverages, and supplements, the Farm Bill draft urges the FDA to expedite rulemaking. It also proposes interim measures to allow CBD products to be marketed as dietary supplements under specific safety and labeling standards, pending final FDA regulations.

This comes as a response to ongoing frustration within the industry over the FDA’s slow pace. Without clear rules, many companies face challenges in product development and market access, while consumers remain uncertain about product safety. If adopted, these provisions could pave the way for broader mainstream acceptance of CBD products.

Implications for Farmers and Businesses

For hemp farmers, the draft bill offers potential relief through enhanced access to federal crop insurance programs, building on earlier reforms. It also seeks to streamline licensing processes, reducing bureaucratic hurdles that have deterred small-scale growers. Industry advocates, such as the U.S. Hemp Roundtable, have praised these measures but are pushing for even stronger protections against state-level overregulation.

For businesses, particularly those in the CBD sector, the proposed clarity around federal oversight could unlock new investment opportunities. However, some stakeholders caution that interim FDA rules might impose strict manufacturing and testing requirements, potentially raising costs for smaller producers.

Industry Reactions and Next Steps

Reactions to the draft are mixed. While many in the hemp industry welcome the focus on research and regulatory clarity, others worry that the bill may not go far enough in addressing issues like interstate commerce barriers for hemp products. “This is a step forward, but we need robust protections to ensure hemp businesses can operate without fear of inconsistent state laws,” said a spokesperson for the National Hemp Association in a recent statement.

The draft is still in early stages, with public hearings and amendments expected over the coming months. Industry stakeholders are gearing up to lobby for their priorities, making this a critical moment for shaping the future of hemp policy in the U.S.

Why This Matters

The 2026 Farm Bill could be a turning point for the hemp and CBD industry, which has faced uncertainty since its federal legalization in 2018. With the global hemp market projected to grow significantly in the coming years, clear and supportive U.S. policies could position American farmers and businesses as leaders in this space. As debates unfold, the outcomes of this legislation will likely influence everything from product innovation to consumer access, making it a key issue to watch in 2026.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.